CJC-1295 DAC 5mg & Ipamorelin 5mg Research Peptide Blend

CJC-1295 DAC 5mg & Ipamorelin 5mg Blend is a dual-peptide research formulation combining a long-acting growth hormone–releasing hormone (GHRH) analog with a selective growth hormone secretagogue (GHS). This blend is studied in laboratory environments for its coordinated interaction with GHRH receptors and ghrelin receptors, allowing researchers to examine sustained and pulsatile growth hormone signaling within experimental models. Supplied as a lyophilized powder with reported purity greater than 99%, this blend is intended exclusively for laboratory research use.

What Is the CJC-1295 DAC & Ipamorelin Blend?

This research blend combines two mechanistically distinct peptides:

• CJC-1295 DAC (5mg): A long-acting GHRH analog engineered with a Drug Affinity Complex to extend biological activity.

• Ipamorelin (5mg): A highly selective growth hormone secretagogue designed to stimulate endogenous growth hormone release via ghrelin receptors.

Together, these peptides are studied for their complementary signaling mechanisms, allowing researchers to evaluate sustained baseline growth hormone stimulation alongside pulsatile release patterns.

This blend is an experimental research formulation and is not approved for human or animal use.

Research Background

Growth hormone regulation involves multiple receptor systems, including GHRH receptors on pituitary somatotroph cells and ghrelin receptors that modulate secretion dynamics. Research protocols frequently examine combinations of GHRH analogs and GHS compounds to better understand how coordinated receptor activation influences growth hormone output and downstream signaling.

CJC-1295 DAC is modified with a lysine-based Drug Affinity Complex, enabling reversible binding to plasma proteins and extending its functional half-life in experimental models to approximately 8 days. Ipamorelin, in contrast, is studied for its short-acting, highly selective stimulation of growth hormone release without significant activation of other pituitary hormones.

All findings remain preclinical.

Mechanisms of Research Interest

Extended Growth Hormone Signaling

CJC-1295 DAC provides prolonged GHRH receptor engagement, enabling research into sustained growth hormone signaling over extended periods.

Pulsatile Growth Hormone Release

Ipamorelin is studied for its ability to stimulate pulsatile growth hormone secretion through selective ghrelin receptor activation.

Receptor Synergy Research

The blend allows researchers to examine how GHRH receptor activation and ghrelin receptor stimulation may work together to enhance endogenous growth hormone signaling in laboratory models.

IGF-1 Pathway Research

Growth hormone release stimulated by this blend is examined for its downstream effects on insulin-like growth factor 1 signaling, a central mediator of anabolic and metabolic pathways.

All mechanisms described are experimental observations or theoretical models and do not imply clinical or therapeutic benefit.

Blend Composition and Molecular Information

CJC-1295 DAC

• Amount: 5 milligrams

• Peptide Length: 29 amino acids

• Molecular Formula: C152H252N44O42

• Molecular Weight: 3367.95 g/mol

Ipamorelin

• Amount: 5 milligrams

• Peptide Length: 5 amino acids

• Molecular Formula: C38H49N9O5

• Molecular Weight: 711.86 g/mol

General Specifications

• Form: Lyophilized powder

• Purity: Greater than 99%

• Classification: Growth hormone signaling research blend

Research Applications

CJC-1295 DAC 5mg & Ipamorelin 5mg Blend may be utilized by qualified researchers in laboratory investigations involving:

• Endogenous growth hormone signaling research

• GHRH and ghrelin receptor pathway studies

• IGF-1–mediated anabolic signaling research

• Endocrine timing and secretion pattern analysis

All use must remain within controlled laboratory environments.

Regulatory Status and Use Disclaimer

• For research use only

• Not approved by the Food and Drug Administration

• Not intended for human or veterinary use

• Not intended to diagnose, treat, cure, or prevent any disease

• No established clinical safety, dosing, or efficacy data